Abstract
Background: Inhaled antibiotics allow the delivery of higher drug concentrations at the site of infection without the systemic adverse effects observed with the use of parenteral or oral antibiotics. These antibiotics have shown to decrease the number of exacerbations, reduce bacterial load or improve pulmonary function in several chronic respiratory conditions. Objectives: The aim of this study was to describe changes in the bacteriology of sputum in patients with chronic bronchial infection with Pseudomonas aeruginosa treated with nebulised colistin. Material and Methods: All patients with chronical infection with P. aeruginosa treated with nebulised colistin attending a day care unit during a 5-year (January 2010 to December 2014) period were included. Repeated-measures t tests were used to assess whether the introduction of colistin was associated with changes in the number of exacerbations or the length of the hospitalisations. Results: Treatment with colistin was associated with a decrease in the number of ambulatory exacerbations (1.87–1.1, p = 0.007), of hospital exacerbations (1.3–0.7, p = 0.010) and of length of stay (15.7–8.6 days, p = 0.005). There was no linear trend in the proportion of isolate Enterobacteriaceae, gram-positive cocci, Haemophilus influenzae or fungi. Isolation of Enterobacteriaceae within 1 year after the beginning of the treatment with nebulised colistin was associated with an increase in the number of ambulatory exacerbations (incidence rate ratio 1.99, 95% CI 1.05–3.79). Conclusions: Nebulised colistin was effective in the treatment of chronic infection with P. aeruginosa, and no significant changes in the microbiological evolution were observed. Isolation of Enterobacteriaceae within 1 year after the beginning of the treatment with nebulised colistin was associated with an increase in the number of exacerbations.
References
1.
Martínez-García
MA
, Soler-Cataluña
JJ
, Perpiñá-Tordera
M
, Román-Sánchez
P
, Soriano
J
. Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis
. Chest
. 2007
Nov
;132
(5
):1565
–72
.
[PubMed]
0012-36922.
Miravitlles
M
, Espinosa
C
, Fernández-Laso
E
, Martos
JA
, Maldonado
JA
, Gallego
M
; Study Group of Bacterial Infection in COPD
. Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD
. Chest
. 1999
Jul
;116
(1
):40
–6
.
[PubMed]
0012-36923.
Finch
S
, McDonnell
MJ
, Abo-Leyah
H
, Aliberti
S
, Chalmers
JD
. A comprehensive analysis of the impact of Pseudomonas aeruginosa colonization on prognosis in adult bronchiectasis
. Ann Am Thorac Soc
. 2015
Nov
;12
(11
):1602
–11
.
[PubMed]
2325-66214.
Almagro
P
, Salvadó
M
, Garcia-Vidal
C
, Rodríguez-Carballeira
M
, Cuchi
E
, Torres
J
, et al. Pseudomonas aeruginosa and mortality after hospital admission for chronic obstructive pulmonary disease
. Respiration
. 2012
;84
(1
):36
–43
.
[PubMed]
1423-03565.
White
L
, Mirrani
G
, Grover
M
, Rollason
J
, Malin
A
, Suntharalingam
J
. Outcomes of Pseudomonas eradication therapy in patients with non-cystic fibrosis bronchiectasis
. Respir Med
. 2012
Mar
;106
(3
):356
–60
.
[PubMed]
0954-61116.
Rubin
BK
, Williams
RW
. Aerosolized antibiotics for non-cystic fibrosis bronchiectasis
. Respiration
. 2014
;88
(3
):177
–84
.
[PubMed]
1423-03567.
Brodt
AM
, Stovold
E
, Zhang
L
. Inhaled antibiotics for stable non-cystic fibrosis bronchiectasis: a systematic review
. Eur Respir J
. 2014
Aug
;44
(2
):382
–93
.
[PubMed]
0903-19368.
Bruguera-Avila
N
, Marin
A
, Garcia-Olive
I
, Radua
J
, Prat
C
, Gil
M
, et al. Effectiveness of treatment with nebulized colistin in patients with COPD
. Int J Chron Obstruct Pulmon Dis
. 2017
Oct
;12
:2909
–15
.
[PubMed]
1176-91069.
Polverino
E
, Rosales-Mayor
E
, Benegas
M
, Menendez
R
, Alcaraz-Serrano
V
, Ansotegui
E
, et al. Pneumonic and non-pneumonic exacerbations in bronchiectasis: clinical and microbiological differences
. [in press]
. J Infect
. 2018
Aug
;77
(2
):99
–106
.
[PubMed]
0163-445310.
Green
H
, Jones
AM
. The microbiome and emerging pathogens in cystic fibrosis and non-cystic fibrosis bronchiectasis
. Semin Respir Crit Care Med
. 2015
Apr
;36
(2
):225
–35
.
[PubMed]
1069-342411.
Noni
M
, Katelari
A
, Kaditis
A
, Theochari
I
, Lympari
I
, Alexandrou-Athanassoulis
H
, et al. Candida albicans chronic colonisation in cystic fibrosis may be associated with inhaled antibiotics
. Mycoses
. 2015
Jul
;58
(7
):416
–21
.
[PubMed]
0933-740712.
Máiz
L
, Nieto
R
, Cantón
R
, Gómez G de la Pedrosa
E
, Martinez-García
MÁ
, Martinez-Garcia
MA
. Fungi in bronchiectasis: a concise review
. Int J Mol Sci
. 2018
Jan
;19
(1
):142
.
[PubMed]
1661-659613.
Naidich
DP
, McCauley
DI
, Khouri
NF
, Stitik
FP
, Siegelman
SS
. Computed tomography of bronchiectasis
. J Comput Assist Tomogr
. 1982
Jun
;6
(3
):437
–44
.
[PubMed]
0363-871514.
Goddard
PR
, Nicholson
EM
, Laszlo
G
, Watt
I
. Computed tomography in pulmonary emphysema
. Clin Radiol
. 1982
Jul
;33
(4
):379
–87
.
[PubMed]
0009-926015.
Clinical and Laboratory Standards Institute
. Performance Standards for Antimicrobial Susceptibility Testing; Twentieth Informational Supplement. Wayne, PA: Clinical and Laboratory Standards Institute; 2010
.16.
Patrick Royston
. 2017
. ptrend: trend analysis for proportions. UCLA: Statistical Consulting Group https://stats.idre.ucla.edu/stata/ado/analysis17.
Emerson
J
, Rosenfeld
M
, McNamara
S
, Ramsey
B
, Gibson
RL
. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis
. Pediatr Pulmonol
. 2002
Aug
;34
(2
):91
–100
.
[PubMed]
8755-686318.
Cullen
L
, McClean
S
. Bacterial adaptation during chronic respiratory infections
. Pathogens
. 2015
Mar
;4
(1
):66
–89
.
[PubMed]
2076-081719.
Kirisits
MJ
, Prost
L
, Starkey
M
, Parsek
MR
. Characterization of colony morphology variants isolated from Pseudomonas aeruginosa biofilms
. Appl Environ Microbiol
. 2005
Aug
;71
(8
):4809
–21
.
[PubMed]
0099-224020.
Chalmers
JD
, Hill
AT
. Mechanisms of immune dysfunction and bacterial persistence in non-cystic fibrosis bronchiectasis
. Mol Immunol
. 2013
Aug
;55
(1
):27
–34
.
[PubMed]
0161-589021.
Maselli
DJ
, Keyt
H
, Restrepo
MI
. Inhaled antibiotic therapy in chronic respiratory diseases
. Int J Mol Sci
. 2017
May
;18
(5
):1062
.
[PubMed]
1661-659622.
Ramsey
BW
, Pepe
MS
, Quan
JM
, Otto
KL
, Montgomery
AB
, Williams-Warren
J
, et al.; Cystic Fibrosis Inhaled Tobramycin Study Group
. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis
. N Engl J Med
. 1999
Jan
;340
(1
):23
–30
.
[PubMed]
0028-479323.
Vendrell
M
, Muñoz
G
, de Gracia
J
. Evidence of inhaled tobramycin in non-cystic fibrosis bronchiectasis
. Open Respir Med J
. 2015
Mar
;9
(1
):30
–6
.
[PubMed]
1874-306424.
Spicuzza
L
, Sciuto
C
, Vitaliti
G
, Di Dio
G
, Leonardi
S
, La Rosa
M
. Emerging pathogens in cystic fibrosis: ten years of follow-up in a cohort of patients
. Eur J Clin Microbiol Infect Dis
. 2009
Feb
;28
(2
):191
–5
.
[PubMed]
0934-972325.
Mahenthiralingam
E
. Emerging cystic fibrosis pathogens and the microbiome
. Paediatr Respir Rev
. 2014
Jun
;15
Suppl 1
:13
–5
.
[PubMed]
1526-055026.
Salsgiver
EL
, Fink
AK
, Knapp
EA
, LiPuma
JJ
, Olivier
KN
, Marshall
BC
, et al. LiPuma JJ, Olivier KN, Marshall BC, Saiman L. Changing epidemiology of the respiratory bacteriology of patients with cystic fibrosis
. Chest
. 2016
Feb
;149
(2
):390
–400
.
[PubMed]
0012-369227.
Goss
CH
, Otto
K
, Aitken
ML
, Rubenfeld
GD
. Detecting Stenotrophomonas maltophilia does not reduce survival of patients with cystic fibrosis
. Am J Respir Crit Care Med
. 2002
Aug
;166
(3
):356
–61
.
[PubMed]
1073-449X28.
Rønne Hansen
C
, Pressler
T
, Høiby
N
, Gormsen
M
. Chronic infection with Achromobacter xylosoxidans in cystic fibrosis patients; a retrospective case control study
. J Cyst Fibros
. 2006
Dec
;5
(4
):245
–51
.
[PubMed]
1569-199329.
De Baets
F
, Schelstraete
P
, Van Daele
S
, Haerynck
F
, Vaneechoutte
M
. Achromobacter xylosoxidans in cystic fibrosis: prevalence and clinical relevance
. J Cyst Fibros
. 2007
Jan
;6
(1
):75
–8
.
[PubMed]
1569-199330.
Woodworth
MH
, Saullo
JL
, Lantos
PM
, Cox
GM
, Stout
JE
. Increasing Nocardia incidence associated with bronchiectasis at tertiary care center
. Ann Am Thorac Soc
. 2017
Mar
;14
(3
):347
–54
.
[PubMed]
2329-693331.
Máiz
L
, Vendrell
M
, Olveira
C
, Girón
R
, Nieto
R
, Martínez-García
MA
. Prevalence and factors associated with isolation of Aspergillus and Candida from sputum in patients with non-cystic fibrosis bronchiectasis
. Respiration
. 2015
;89
(5
):396
–403
.
[PubMed]
1423-035632.
Nicotra
MB
, Rivera
M
, Dale
AM
, Shepherd
R
, Carter
R
. Clinical, pathophysiologic, and microbiologic characterization of bronchiectasis in an aging cohort
. Chest
. 1995
Oct
;108
(4
):955
–61
.
[PubMed]
0012-369233.
Chalmers
JD
, Goeminne
P
, Aliberti
S
, McDonnell
MJ
, Lonni
S
, Davidson
J
, et al. The bronchiectasis severity index. An international derivation and validation study
. Am J Respir Crit Care Med
. 2014
Mar
;189
(5
):576
–85
.
[PubMed]
1073-449X34.
Chalmers
JD
, Moffitt
KL
, Suarez-Cuartin
G
, Sibila
O
, Finch
S
, Furrie
E
, et al. Neutrophil elastase activity is associated with exacerbations and ung function decline in bronchiectasis. Am J respire
. Am J Respir Crit Care Med
. 2017
May
;195
(10
):1384
–93
.
[PubMed]
1073-449X35.
Samonis
G
, Korbila
IP
, Maraki
S
, Michailidou
I
, Vardakas
KZ
, Kofteridis
D
, et al. Trends of isolation of intrinsically resistant to colistin Enterobacteriaceae and association with colistin use in a tertiary hospital
. Eur J Clin Microbiol Infect Dis
. 2014
Sep
;33
(9
):1505
–10
.
[PubMed]
0934-972336.
McDonnell
MJ
, Jary
HR
, Perry
A
, MacFarlane
JG
, Hester
KL
, Small
T
, et al. Non cystic fibrosis bronchiectasis: A longitudinal retrospective observational cohort study of Pseudomonas persistence and resistance
. Respir Med
. 2015
Jun
;109
(6
):716
–26
.
[PubMed]
0954-611137.
Menéndez
R
, Méndez
R
, Polverino
E
, Rosales-Mayor
E
, Amara-Elori
I
, Reyes
S
, et al. Factors associated with hospitalization in bronchiectasis exacerbations: a one-year follow-up study
. Respir Res
. 2017
Sep
;18
(1
):176
.
[PubMed]
1465-992138.
Hodson
ME
, Gallagher
CG
, Govan
JR
. A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis
. Eur Respir J
. 2002
Sep
;20
(3
):658
–64
.
[PubMed]
0903-1936© 2019 S. Karger AG, Basel
2019
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
